| 摘要 |
<p>The onset ratios and pathological conditions of collagen-induced arthritis (CIA) and adjuvant arthritis (AA) in model mice are successfully ameliorated by topically expressing cyclin-dependent kinase inhibitor (CDKI) p161NK4a and p21Cip1 proteins in articular tissues. In the synovial cells of the mice with the induction of CDKI, the expression of inflammatory cytokines (IL-1β, IL-6, TNF-α, etc.) are inhibited. The p21Cip1 protein to be used for inhibiting the abnormal proliferation of synovial tissues, inflammation in synovial tissues and/or the expression of inflammatory cytokines in synovial tissues; a p21Cip1 gene; a compound promoting the activity or expression of the above protein; medicinal compositions containing these molecules; and a method of screening a compound participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and/or the expression of inflammatory cytokines in synovial tissues targeting the p21Cip1 protein. Rheumatoid arthritis and the like can be prevented or treated by gene therapy with the use of, for example, p21Cip1.</p> |
